Patients must be amyloid positive - shown through amyloid PET scan, CSF results, or blood test results.

At the consultation appointment:

• Dr. Kerwin will evaluate candidacy for LEQEMBI and review potential risks and benefits.
• Dr. Kerwin will order any additional testing (for example, PET, genotyping, or neuropsychological evaluation) required to evaluate candidacy and will review results with patients once they are received.
• Infusion and safety MRI schedule will be reviewed with the patient and tentatively scheduled.
• KMC will submit an enrollment request for Eisai's Patient Support Program, which provides benefits verification, prior authorization services, and evaluates eligibility for financial assistance.
• For patients with Medicare, Kerwin Medical Center will submit patient information to the CMS database as required for Medicare coverage of LEQEMBI. 

Clinical documentation required with a referral for LEQEMBI infusions:

• Documentation of diagnosis of Mild Cognitive Impairment or Alzheimer's Disease
• Brain MRI without contrast from the past 12 months
• Lab results from the past 6 months: CMP, CBC, coagulation labs

If available, please also include:

• Documentation of amyloid status (Amyloid pet, CSF, or blood test results)
• Results of ApoE4 genotyping
• Neuropsychological evaluation(s)

KMC does require APOE testing to rule out complications associated with specific genetic profiles. 

Patients who haven't already completed APOE testing can order at-home APOE test kits to obtain their APOE status prior to a consultation appointment for Leqembi.

Kerwin Medical Center currently accepts Medicare part B, which covers 80% of costs associated with Leqembi. The patient is responsible for their 20% coinsurance.

Credentialing with Medicare supplement plans coming soon!